283 related articles for article (PubMed ID: 27497846)
1. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
3. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
7. Anagrelide treatment in myeloproliferative disorders.
Birgegard G
Semin Thromb Hemost; 2006 Apr; 32(3):260-6. PubMed ID: 16673280
[TBL] [Abstract][Full Text] [Related]
8. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
9. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
10. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
11. Treatment of essential thrombocythemia with anagrelide.
Chintagumpala MM; Kennedy LL; Steuber CP
J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
[TBL] [Abstract][Full Text] [Related]
12. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
13. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.
Besses C; Kiladjian JJ; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Abhyankar B; Birgegård G
Leuk Res; 2013 Feb; 37(2):162-8. PubMed ID: 23199894
[TBL] [Abstract][Full Text] [Related]
15. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
17. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
18. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
[TBL] [Abstract][Full Text] [Related]
19. Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases.
Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Noguchi M
Gan To Kagaku Ryoho; 2019 Jul; 46(7):1141-1150. PubMed ID: 31296820
[TBL] [Abstract][Full Text] [Related]
20. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
